Psychoemotional disorders of patients with inflammatory bowel diseases: prevalence, pathogenesis and treatment options

Abstract

Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, according to the World Gastroenterological Organization occupy one of the leading places in the structure of diseases of the gastrointestinal tract of the rate of spread and relevance of research in most countries of the world. The currently existing therapy regimens, which are standardized depending on the form of the disease and the severity of the course, do not take into account the psycho-emotional component of the disease. Progressive course, frequent exacerbations, restriction of social activity, the presence of extra-intestinal manifestations and complications lead to early disability and significantly worsen the quality of life of patients with inflammatory bowel disease.

Keywords

inflammatory bowel disease / ulcerative colitis / Crohn’s disease / psycho-emotional state / brain-gut axis / quality of life

References

[1] Inflammatory Bowel Disease [Internet]. World Gastroenterology Organisation. Available from: https://www.worldgastroenterology.org/guidelines/inflammatory-bowel-disease-ibd. Accessed: 25.05.2023.

[2] Inflammatory Bowel Disease [Электронный ресурс] // World Gastroenterology Organisation. Режим доступа: https://www.worldgastroenterology.org/guidelines/inflammatory-bowel-disease-ibd. Дата обращения: 25.05.2023.

[3] Klinicheskie rekomendatsii “Yazvennyy kolit” [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyikolit-utv-minzdravom-rossii. Accessed: 18.09.2021. (In Russ.)

[4] Клинические рекомендации «Язвенный колит» [Электронный ресурс] // Минздрав РФ. Режим доступа: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyi-kolit-utv-minzdravom-rossii. Дата обращения: 18.09.2021.

[5] Ivashkin VT, Shelygin YuA, Abdulganieva DI, et al. Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2(72)):8–38. (In Russ.) DOI: 10.33878/2073-7556-2020-19-2-8-38

[6] Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект) // Колопроктология. 2020. Т. 19, № 2(72). С. 8–38. DOI: 10.33878/2073-7556-2020-19-2-8-38

[7] Knyazev OV, Shkurko TV, Fadeyeva NA, et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;139(3):4–12. (In Russ.)

[8] Князев О.В., Шкурко Т.В., Фадеева Н.А. и др. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра // Экспериментальная и клиническая гастроэнтерология. 2017. Т. 139, № 3. С. 4–12.

[9] Bakulin IG, Skalinskaya MI, Skazyvaeva EV. North-Western register of patients with inflammatory bowel diseases: achievements and lessons learned. Koloproktologia. 2022;21(1):37–49. (In Russ.) DOI: 10.33878/2073-7556-2022-21-1-37-49

[10] Бакулин И.Г., Скалинская М.И., Сказываева Е.В. Северо-Западный регистр пациентов с воспалительными заболеваниями кишечника: достижения и уроки // Колопроктология. 2022. № 1(21). С. 37–49. DOI: 10.33878/2073-7556-2022-21-1-37-49

[11] Bakulin IG, Skalinskaya MI, Maev IG, et al. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Тerapevticheskii Arkhiv. 2021;8(93):841–852. (In Russ.) DOI: 10.26442/00403660.2021.08.200982

[12] Бакулин И.Г., Скалинская М.И., Маев И.В. и др. Фармакотерапия воспалительных заболеваний кишечника: управление эффективностью и безопасностью // Терапевтический архив. 2021. Т. 93, № 8. С. 841–852. DOI: 10.26442/00403660.2021.08.200982

[13] Keller R, Mazurak N, Fantasia L, et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel. Intest Res. 2021;19(1):45–52. DOI: 10.5217/ir.2019.00135

[14] Keller R., Mazurak N., Fantasia L. et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel // Intest. Res. 2021. Vol. 19, No. 1. P. 45–52. DOI: 10.5217/ir.2019.00135

[15] Knowles SR, Graff LA, Wilding H, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part I. Inflamm Bowel Dis. 2018;4(24):742–751. DOI: 10.1093/ibd/izx100

[16] Knowles S.R., Graff L.A., Wilding H. et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I // Inflamm. Bowel Dis. 2018. Vol. 24, No. 4. P. 742–751. DOI: 10.1093/ibd/izx100

[17] Maev IV, Shelygin YuA, Skalinskaya MI, et al. Pathomorphosis of inflammatory bowel diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35. (In Russ.) DOI: 10.15690/vramn1219

[18] Маев И.В., Шелыгин Ю.А., Скалинская М.И. и др. Патоморфоз воспалительных заболеваний кишечника // Вестник Российской академии медицинских наук. 2020. Т. 75, № 1. С. 27–35. DOI: 10.15690/vramn1219

[19] Ozer M, Bengi G, Colak R, et al. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life. Medicine (Baltimore). 2020;99(19):e20067. DOI: 10.1097/MD.0000000000020067

[20] Ozer M., Bengi G., Colak R. et al. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life // Medicine (Baltimore). 2020. Vol. 99, No. 19. P. e20067. DOI: 10.1097/MD.0000000000020067

[21] Alexander F. Psychosomatic medicine. Principles and application. Transl. by A.M. Bokovikov, V.V. Starovoitov. Ed. by S.L. Shishkin. Moscow; 2006. (In Russ.)

[22] Александер Ф. Психосоматическая медицина. Принципы и применение / пер. с англ. А.М. Боковикова, В.В. Старовойтова / под ред. С.Л. Шишкина. Москва, 2006.

[23] James PH, Jessica MM, Sriparna G, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016;6(2):603–621. DOI: 10.1002/cphy.c150015

[24] Herman J.P., McKlveen J.M., Ghosal S. et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response // Compr. Physiol. 2016. Vol. 2, No. 6. P. 603–621. DOI: 10.1002/cphy.c150015

[25] Martin-Subero M, Anderson G, Kanchanatawan B, et al. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 2016;21(2):184–198. DOI: 10.1017/S1092852915000449

[26] Martin-Subero M., Anderson G., Kanchanatawan B. et al. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways // CNS Spectr. 2016. Vol. 21, No. 2. P. 184–198. DOI: 10.1017/S1092852915000449

[27] Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–148. DOI: 10.1016/j.jcmgh.2018.04.003

[28] Martin C.R., Osadchiy V., Kalani A., Mayer E.A. The brain-gut-microbiome axis // Cell. Mol. Gastroenterol. Hepatol. 2018. Vol. 6, No. 2. P. 133–148. DOI: 10.1016/j.jcmgh.2018.04.003

[29] Ilchmann-Diounou H, Menard S. Psychological stress, intestinal barrier dysfunctions, and autoimmune disorders: an overview. Front Immunol. 2020;11:133–148. DOI: 10.3389/fimmu.2020.01823

[30] Ilchmann-Diounou H., Menard S. Psychological stress, intestinal barrier dysfunctions, and autoimmune disorders: an overview // Front. Immunol. 2020. Vol. 11. P. 133–148. DOI: 10.3389/fimmu.2020.01823

[31] Psikhosomaticheskie rasstroistva v praktike terapevta. (authors) Vinokur V.A., Grinevich V.B., Il’yashevich I.G. et al. Saint Petersburg: SpecLit; 2008. P. 65–84. (In Russ.)

[32] Психосоматические расстройства в практике терапевта / В.А. Винокур, В.Б. Гриневич, И.Г. Ильяшевич и др. Санкт-Петербург: СпецЛит, 2008. С. 65–84.

[33] Sinniger V, Pellissier S, Fauvelle F, et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterol Motil. 2018;32(10):e13911. DOI: 10.1111/nmo.13911

[34] Sinniger V., Pellissier S., Fauvelle F. et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease // Neurogastroenterol. Motil. 2018. Vol. 32, No. 10. DOI: 10.1111/nmo.13911

[35] Ge L, Liu S, Li S, et al. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications. Front Immunol. 2022;13:1016578. DOI: 10.3389/fimmu.2022.1016578

[36] Ge L., Liu S., Li S. et al. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications // Front. Immunol. 2022. Vol. 13. P. 1016578. DOI: 10.3389/fimmu.2022.1016578

[37] Meroni E, Stakenborg N, Gomez-Pinilla PJ, et al. Vagus nerve stimulation promotes epithelial proliferation and controls colon monocyte infiltration during DSS-induced colitis. Front Med (Lausanne). 2021;8:694268. DOI: 10.3389/fmed.2021.694268

[38] Meroni E., Stakenborg N., Gomez-Pinilla P.J. et al. Vagus nerve stimulation promotes epithelial proliferation and controls colon monocyte infiltration during DSS-induced colitis // Front. Med. (Lausanne). 2021. Vol. 8. P. 694268. DOI: 10.3389/fmed.2021.694268

[39] Chen LM, Bao CH, Wu Y, et al. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease. J Neuroinflammation. 2021;18(1):135. DOI: 10.1186/s12974-021-02175-2

[40] Chen L.M., Bao C.H., Wu Y. et al. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease // J. Neuroinflammation. 2021. Vol. 18, No. 1. P. 135. DOI: 10.1186/s12974-021-02175-2

[41] Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3–10. DOI: 10.1016/j.autrev.2013.06.004

[42] Geremia A., Biancheri P., Allan P. et al. Innate and adaptive immunity in inflammatory bowel disease // Autoimmun. Rev. 2014. Vol. 13, No. 1. P. 3–10. DOI: 10.1016/j.autrev.2013.06.004

[43] Byrne G, Rosenfeld G, Leung Y, et al. Prevalence of anxiety and depression in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:6496727. DOI: 10.1155/2017/6496727

[44] Byrne G., Rosenfeld G., Leung Y. et al. Prevalence of anxiety and depression in patients with inflammatory bowel disease // Can. J. Gastroenterol. Hepatol. 2017. Vol. 2017. P. 6496727. DOI: 10.1155/2017/6496727

[45] Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12(8):697–707. DOI: 10.1097/00054725-200608000-00005

[46] Fuller-Thomson E., Sulman J. Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys // Inflamm. Bowel Dis. 2006. Vol. 12, No. 8. P. 697–707. DOI: 10.1097/00054725-200608000-00005

[47] Yongwen NgJ, Chauhan U, Armstrong D, et al. Comparison of the prevalence of anxiety and depression between uncomplicated and complex IBD patient groups. Gastroenterol Nurs. 2018;41(5):427–435. DOI: 10.1097/SGA.0000000000000338

[48] Yongwen Ng.J., Chauhan U., Armstrong D. et al. Comparison of the prevalence of anxiety and depression between uncomplicated and complex IBD patient groups // Gastroenterol. Nurs. 2018. Vol. 41, No. 5. P. 427–435. DOI: 10.1097/SGA.0000000000000338

[49] Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2018;22(3):752–762. DOI: 10.1097/MIB.0000000000000620

[50] Mikocka-Walus A., Knowles S.R., Keefer L., Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases // Inflamm. Bowel Dis. 2018. Vol. 22, No. 3. P. 752–762. DOI: 10.1097/MIB.0000000000000620

[51] Stamboltsyan VSh. Otsenka urovnya ispytuemogo stressa i ehmotsional’noi ustoichivosti u bol’nykh s vospalitel’nymi zabolevaniyami kishechnika. Proceedings of the all-Russian scientific and practical conference with international participation “Mechnikov readings”; Saint Petersburg: 25–26 Apr 2018. Saint Petersburg; 2018. P. 98. (In Russ.)

[52] Стамболцян В.Ш. Оценка уровня испытуемого стресса и эмоциональной устойчивости у больных с воспалительными заболеваниями кишечника // Материалы Всероссийской научно-практической конференции с международным участием «Мечниковские чтения – 2018», Санкт-Петербург, 25–26 апреля 2018 г. Санкт-Петербург, 2018. С. 98.

[53] Lewis K, Marrie RA, Bernstein CN, et al. The Prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(10):1674–1680. DOI: 10.1093/ibd/izz045

[54] Lewis K., Marrie R.A., Bernstein C.N. et al. The Prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease // Inflamm. Bowel Dis. 2019. Vol. 25, No. 10. P. 1674–1680. DOI: 10.1093/ibd/izz045

[55] Romasenko LV, Makhov VM, Isaykina MA. Disorders of the anxiety-depressive spectrum in inflammatory bowel diseases (psychosomatic correlations). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):9–13. (In Russ.) DOI: 10.17116/jnevro20191190419

[56] Ромасенко Л.В., Махов В.М., Исайкина М.А. Расстройства тревожно-депрессивного спектра при воспалительных заболеваниях кишечника (психосоматические соотношения) // Журнал неврологии и психиатрии им. С.С. Корсакова. 2019. Т. 119, № 4. С. 9–13. DOI: 10.17116/jnevro20191190419

[57] Yuan X, Chen B, Duan Z, et al. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes. 2021;13(1):1987779. DOI: 10.1080/19490976.2021.1987779

[58] Yuan X., Chen B., Duan Z. et al. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics // Gut Microbes. 2021. Vol. 13, No. 1. P. 1987779. DOI: 10.1080/19490976.2021.1987779

[59] Araki M, Shinzaki S, Yamada T, et al. Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study. PLoS One. 2020;5(15):e0233365. DOI: 10.1371/journal.pone.0233365

[60] Araki M., Shinzaki S., Yamada T. et al. Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study // PLoS One. 2020. Vol. 15, No. 5. P. e0233365. DOI: 10.1371/journal.pone.0233365

[61] Paulides E, Boukema I, van der Woude CJ, de Boer NKH. The Effect of psychotherapy on quality of life in IBD patients: a systematic review. Inflamm Bowel Dis. 2021;27(5):711–724. DOI: 10.1093/ibd/izaa144

[62] Paulides E., Boukema I., van der Woude C.J., de Boer N.K.H. The effect of psychotherapy on quality of life in IBD patients: a systematic review // Inflamm. Bowel Dis. 2021. Vol. 27, No. 5. P. 711–724. DOI: 10.1093/ibd/izaa144

[63] Iskandar HN, Cassell B, Kanuri N, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol. 2014;48(5):423–429. DOI: 10.1097/MCG.0000000000000049

[64] Iskandar H.N., Cassell B., Kanuri N. et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease // J. Clin. Gastroenterol. 2014. Vol. 48, No. 5. P. 423–429. DOI: 10.1097/MCG.0000000000000049

[65] Guemei AA, El Din NM, Baraka AM, El Said Darwish I. Do desipramine [10,11-Dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b, f]azepine monohydrochloride] and Fluoxetine [N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats? J Pharmacol Exp Ther. 2008;327(3):846–850. DOI: 10.1124/jpet.108.141259

[66] Guemei A.A., El Din N.M., Baraka A.M., El Said Darwish I. Do desipramine [10,11-Dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b, f]azepine monohydrochloride] and Fluoxetine [N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in Rats? // J. Pharmacol. Exp. Ther. 2008. Vol. 327, No. 3. P. 846–850. DOI: 10.1124/jpet.108.141259

[67] Kristensen MS, Kjærulff TM, Ersbøll AK, et al. The influence of antidepressants on the disease course among patients with Crohn’s disease and ulcerative colitis-A Danish Nationwide Register-Based Cohort Study. Inflamm Bowel Dis. 2019;25(5):886–893. DOI: 10.1093/ibd/izy367

[68] Kristensen M.S., Kjærulff T.M., Ersbøll A.K. et al. The influence of antidepressants on the disease course among patients with Crohn’s disease and ulcerative colitis-A Danish Nationwide Register-Based Cohort Study // Inflamm. Bowel Dis. 2019. Vol. 25, No. 5. P. 886–893. DOI: 10.1093/ibd/izy367

RIGHTS & PERMISSIONS

Eco-Vector